7 Most Promising Gene Editing Stocks According to Analysts

Page 6 of 6

1. Wave Life Sciences Ltd. (NASDAQ:WVE)

Price Target Upside: 99.49%

Wave Life Sciences Ltd. (NASDAQ:WVE) tops our list for being one of the most promising stocks. 

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an Outperform rating, citing highly encouraging interim Phase 1 data for WVE‑007, an investigational siRNA therapy that showed meaningful reductions in visceral and total body fat alongside lean mass increases in the INLIGHT trial.

Truist Financial followed on December 15, boosting its price target to $50 from $36 and reaffirming a Buy rating, highlighting clinical durability and safety as key valuation drivers.

Wave Life Sciences Ltd. (NASDAQ:WVE) ’s December 8 Phase 1 INLIGHT results for WVE‑007 demonstrated a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat at three months after a single 240 mg dose, along with increased lean mass, differentiating it from many existing obesity therapies and supporting the broader opportunity in metabolic diseases.

Financially, WVE strengthened its balance sheet via an upsized ~$402.5 million public offering priced at $19 per share on December 9, providing runway into late 2028 to advance WVE‑007 and other RNA programs.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical‑stage genetic medicines company developing RNA‑targeting therapeutics for genetically defined diseases. Its proprietary PRISM platform designs stereopure oligonucleotides for RNA editing, splicing, RNA interference (RNAi), and antisense silencing to precisely modulate gene expression and protein production.

While we acknowledge the potential of WVE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WVE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. 7 Most Promising Gene Editing Stocks According to Analysts is originally published on Insider Monkey. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 6 of 6